Anika Therapeutics (ANIK) Expected to Announce Earnings on Wednesday

Anika Therapeutics (NASDAQ:ANIK) will likely be posting its Q1 2026 results before the market opens on Wednesday, April 29th. Analysts expect Anika Therapeutics to post earnings of ($0.07) per share and revenue of $28.1420 million for the quarter. Individuals may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, April 29, 2026 at 8:30 AM ET.

Anika Therapeutics (NASDAQ:ANIK) last announced its earnings results on Thursday, February 26th. The biotechnology company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.29. The company had revenue of $30.62 million for the quarter, compared to analyst estimates of $28.88 million. Anika Therapeutics had a negative return on equity of 6.26% and a negative net margin of 9.64%. On average, analysts expect Anika Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Anika Therapeutics Trading Down 4.9%

Shares of NASDAQ ANIK opened at $15.04 on Wednesday. The firm has a market cap of $201.55 million, a P/E ratio of -19.79 and a beta of 0.28. Anika Therapeutics has a 1-year low of $7.87 and a 1-year high of $16.24. The business’s 50 day moving average is $13.71 and its 200-day moving average is $11.05.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Anika Therapeutics in a research note on Monday, December 29th. Barrington Research increased their target price on Anika Therapeutics from $16.00 to $17.00 and gave the stock an “outperform” rating in a research note on Friday, February 27th. Finally, Wall Street Zen upgraded Anika Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $17.00.

Institutional Investors Weigh In On Anika Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Quarry LP acquired a new stake in Anika Therapeutics during the third quarter worth approximately $71,000. Occudo Quantitative Strategies LP acquired a new stake in Anika Therapeutics during the third quarter worth approximately $95,000. Ieq Capital LLC acquired a new stake in Anika Therapeutics during the fourth quarter worth approximately $97,000. Mercer Global Advisors Inc. ADV acquired a new stake in Anika Therapeutics during the fourth quarter worth approximately $122,000. Finally, Jain Global LLC acquired a new stake in Anika Therapeutics during the fourth quarter worth approximately $137,000. Institutional investors and hedge funds own 91.53% of the company’s stock.

About Anika Therapeutics

Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika’s proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.

The company’s core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets.